710
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Polycaprolactone-based in situ implant containing curcumin-PLGA nanoparticles prepared using the multivariate technique

, , , , &
Pages 1520-1528 | Received 28 Mar 2015, Accepted 02 Jun 2015, Published online: 29 Jun 2015

References

  • Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB. 2009. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 79:330–338.
  • Bilati U, Allémann E, Doelker E. 2003. Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharm Dev Technol. 8:1–9.
  • Chuah LH, Billa N, Roberts CJ, Burley JC, Manickam S. 2013. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm Dev Technol. 18:591–599.
  • Esmaeilzadeh-Gharedaghi E, Faramarzi MA, Amini MA, Rouholamini Najafabadi A, Rezayat SM, Amani A. 2012. Effects of processing parameters on particle size of ultrasound prepared chitosan nanoparticles: An Artificial Neural Networks Study. Pharm Dev Technol. 17:638–647.
  • Ferreira AP, Tobyn M. 2014. Multivariate analysis in the pharmaceutical industry: enabling process understanding and improvement in the PAT and QbD era. Pharm Dev Technol. 1–15.
  • Ferreira SL, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, et al. 2007. Box-Behnken design: An alternative for the optimization of analytical methods. Anal Chim Acta. 597:179–186.
  • Gao Y, Li Z, Sun M, Li H, Guo C, Cui J, et al. 2010. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm. 36:1225–1234.
  • Gosangari S, Dyakonov T. 2013. Enhanced dissolution performance of curcumin with the use of supersaturatable formulations. Pharm Dev Technol. 18:475–480.
  • Gosangari SL, Watkin KL. 2012. Effect of preparation techniques on the properties of curcumin liposomes: Characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line. Pharm Dev Technol. 17:103–109.
  • Guideline ICHHT. 2009. Pharmaceutical development. Q8 (2R). As revised in August.
  • Jagani H, Kasinathan N, Meka SR, Josyula VR. 2015. Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review. Artif Cells Nanomed Biotechnol. 24:1–10.
  • Jelvehgari M, Hassanzadeh D, Kiafar F, Loveym BD, Amiri S. 2011. Preparation and determination of drug-polymer interaction and in-vitro release of mefenamic acid microspheres made of celluloseacetate phthalate and/or ethylcellulose polymers. Iran Journal Pharm Res. 10:457–467.
  • Kasinathan N, Amirthalingam M, Reddy ND, Jagani HV, Volety SM, Rao JV. 2014a. In-situ implant containing PCL-curcumin nanoparticles developed using design of experiments. Drug Deliv. 23:1–9.
  • Kasinathan N, Jagani HV, Alex AT, Volety SM, Rao JV. 2014b. Strategies for drug delivery to the central nervous system by systemic route. Drug delivery. 1–15.
  • Khalil NM, Nascimento TCFD, Casa DM, Dalmolin LF, Mattos ACD, Hoss I, et al. 2013. Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces. 101:353–360.
  • Koganti S, Jagani HV, Palanimuthu VR, Mathew JA, Rao MC, Rao JV. 2013. In vitro and in vivo evaluation of the efficacy of nanoformulation of siRNA as an adjuvant to improve the anticancer potential of cisplatin. Exp Mol Pathol. 94:137–147.
  • Yu LX. 2008. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 25:781–791.
  • Leleux J, Williams RO. 2013. Recent advancements in mechanical reduction methods: particulate systems. Drug Dev Ind Pharm. 1–12.
  • Lionberger RA, Lee SL, Lee L, Raw A, Lawrence XY. 2008. Quality by design: concepts for ANDAs. AAPS J. 10:268–276.
  • Narayanan K, Subrahmanyam VM, Rao JV. 2014. Application of experimental design in preparation of nanoliposomes containing hyaluronidase. J Drug Deliv. 2014:948650.
  • Packhaeuser CB, Schnieders J, Oster CG, Kissel T. 2004. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 58:445–455.
  • Pal S, Choudhuri T, Chattopadhyay S, Bhattacharya A, Datta GK, Das T, Sa G. 2001. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem Biophys Res Commun. 288:658–665.
  • Piñón-Segundo E, Nava-Arzaluz MG, Lechuga-Ballesteros D. 2012. Pharmaceutical Polymeric Nanoparticles Prepared by the Double Emulsion-Solvent Evaporation Technique. Recent Pat Drug Deliv Formul. 6:224–235.
  • Ranjan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK. 2013. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Research. 33:3603–3609.
  • Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK. 2012. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnology. 10:38.
  • Raveendran R, Bhuvaneshwar GS, Sharma CP. 2013. In vitro cytotoxicity and cellular uptake of curcumin-loaded Pluronic/Polycaprolactone micelles in colorectal adenocarcinoma cells. J Biomater Appl. 27:811–827.
  • Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, Zarghami N, Taheri-Anganeh M, Zeighamian V, et al. 2014. A Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells Nanomed Biotechnol. 17:1–8.
  • Yallapu MM, Jaggi M, Chauhan SC. 2012. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 17:71–80.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.